表皮生长因子受体(EGFR,ErbB)家族在特异性配体的诱导下能够发生家族成员的二聚化,从而激活细胞内下游信号转导途径,调控细胞的增殖、分化、迁移等生物效应。异常的ErbB受体信号与口腔肿瘤的发生发展有着密切的关系。其在多种口腔肿瘤中表达或高表达,可作为评估和判断口腔鳞癌细胞增殖状态、恶性度及患者预后的参考指标。以ErbB受体为靶点的抗肿瘤药物成为近年来口腔肿瘤治疗研究中的热点领域。 Epidermal growth factor receptor (EGFR, ErbB) family can induce dimerization of family members under the induction of specific ligands, thereby activating the intracellular downstream signal transduction pathway and regulating the biological effects such as cell proliferation, differentiation and migration. Abnormal ErbB receptor signaling and the occurrence and development of oral tumors are closely related. Its expression or overexpression in many oral tumors can be used as a reference index for evaluating and judging the proliferation status, malignancy and prognosis of oral squamous cell carcinoma. Antitumor drugs targeting ErbB receptors have become a hot area in oral cancer therapy in recent years.